Citigroup
PMCB icon

Citigroup’s PharmaCyte Biotech PMCB Stock Holding History

Citigroup’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$1 – 6364
2025
Q3 		$1 Buy
+1
New +$1 ﹤0.01% 6040

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Citigroup's PMCB Position: Q4 2025 in Review

Citigroup sold out of PharmaCyte Biotech (PMCB) in Q4 2025, closing a stake of 1 share — an estimated $1 sold.

Citigroup first reported a position in PMCB in Q3 2025 and held it in 1 quarter. The position peaked at $1 in Q3 2025. 28 funds tracked by Wall St. Rank hold PMCB as of Q4 2025.

  • Citigroup reported no remaining PharmaCyte Biotech position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 1 PharmaCyte Biotech share in Q4 2025, an estimated $1.
  • Citigroup first reported a position in PharmaCyte Biotech in Q3 2025 and held it in 1 quarter.
  • Citigroup's PharmaCyte Biotech position peaked at $1 in Q3 2025.
  • 28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.